Insider Cluster (1 insider) ·Filed Mar 6, 2026

UTHR

UNITED THERAPEUTICS Corp
NEUTRAL
Impact 3/10
Horizondays Processed6mo ago
Insider cluster: 2 insiders, $443K total
Actionable Insight • Neutral

Monitor for Form 144 filings or future clusters to determine if this is part of a larger divestment trend. Given the small size relative to market cap and CEO's history of structured trades, this is likely routine.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
UTHR ▲ +14.53% at T+60d
NEUTRAL call ✓ call won +14.53% · α vs SPY +1.75% · entry $475.52 → $544.62
Entry anchored
Mar 5, 03:59 PM ET
via exchange tick
T+1d
+10.70%
call +10.70% · α +9.85%
$526.40
settled 7mo ago
T+5d
+12.71%
call +12.71% · α +14.24%
$535.95
settled 7mo ago
T+20d
+16.94%
call +16.94% · α +18.98%
$556.07
settled 6mo ago
T+60d
+14.53%
call +14.53% · α +1.75%
$544.62
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

United Therapeutics CEO Martine Rothblatt sold 1,156 shares in two open-market transactions totaling $616,635 over the past week, while also exercising options for 19,000 shares at a mix of $0 and $146.03 strike prices. The sales represent a small fraction of market cap and are likely part of pre-arranged trading plans or tax-related activity following option exercises.

Key Financial Metrics

Direction
selling
Total Value
$616.6K
Insiders
1

Key Facts

  • CEO Martine Rothblatt sold 1,156 shares in open-market transactions for $616,635 over two days.
  • Concurrent with the sales, Rothblatt exercised 19,000 derivative securities, including 9,500 shares at $0 (likely RSU vesting) and 9,500 at $146.03 (in-the-money options).
  • Total open-market sale value: $616,635 — approximately 0.0026% of $23.5B market cap.
  • All transactions occurred within a 5-day window, suggesting coordinated activity likely tied to option exercise and tax obligations.

Financial Impact

$616,635 in open-market sales; $1.39M in derivative exercises (non-cash)

insider ownershippotential dilution

Risk Factors

  • Perception of insider selling could weigh on sentiment if misinterpreted.
  • Future larger-scale selling may signal reduced confidence, though current activity is not indicative.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CONTEXT: Insider Cluster Data (4 trades, 7d window)cluster-UTHR-1773664262597
91 reports for UTHR
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+60▲ +5.53%Feb 25, 2026
Filters
Rows
Reports for UTHR — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Cluster
NEUTRAL ★ 2/10
$500.35 $497.31▼ −0.61%▼ −2.72%$571.38 (+14.20%)
Sep 11, 2026
21d ago
Insider Cluster
NEUTRAL ★ 3/10
$497.11 $494.63▼ −0.50%▼ −0.28%$571.38 (+14.94%)
Sep 10, 2026
22d ago
Insider Cluster
MIXED ★ 4/10
$503.86 $497.27▼ −1.31%▼ −0.81%$571.38 (+13.40%)
Sep 9, 2026
23d ago
Insider Cluster
NEUTRAL ★ 3/10
$506.82 $498.48▼ −1.65%▼ −0.99%$571.38 (+12.74%)
Sep 4, 2026
28d ago
Insider Cluster
NEUTRAL ★ 2/10
$487.61 $502.70▲ +3.09%▲ +4.30%$571.38 (+17.18%)
Sep 3, 2026
29d ago
Insider Cluster
NEUTRAL ★ 2/10
$488.16 $497.11▲ +1.83%▲ +2.98%$571.38 (+17.05%)
Aug 28, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$515.46 $487.61▼ −5.40%▼ −5.51%$571.38 (+10.85%)
Aug 27, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$527.91 $492.02▼ −6.80%▼ −6.03%$571.38 (+8.23%)
Aug 26, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$516.68 $492.02▼ −4.77%▼ −4.65%$571.38 (+10.59%)
Aug 25, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$516.68 $492.02▼ −4.77%▼ −4.65%$571.38 (+10.59%)
Showing 10 of 91

US Market Status

Market Open — Closes in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Mar 16, 2026